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ackground: Carcinoma of the breast is the most prevalent cause of mortality from cancer in women aged 
40-69 years. The aim of the present study was to examine any alteration in the status of lactate 
dehydrogenase, ferritin, gamma glutamyl transferase, Platelets, hemoglobin, alkaline phosphatase, 
aspartate transaminase, alanine transferase and bilirubin in the plasma of breast cancer patients without 
distant metastasis, to establish their diagnostic and prognostic values. 
Methods: Current reading describes a study conducted on 50 breast cancer patients from Institute of Nuclear 
Medicine and Oncology (Lahore). The patients were clinically categorized as stage II (19 patients) and stage III 
(29 patients) respectively. Most of the patients were diseased with infiltrative ductal carcinoma (48) of the breast. 
Blood samples of all patients were collected after forty days of chemotherapy course besides 10 healthy 
subjects.  
Results: There was a significant rise in LDH (221.48 ± 18.44) and Ferritin (356.46 ± 12.28) levels as compared 
to control groups. Concentration of GGT (34.12 ± 1.61) was also elevated but not significantly raised. There was 
no significant rise in ALP (279.27 ± 26.60), AST (49.44 ± 8.510), ALT (33.40 ± 2.83), bilirubin (4.87 ± 3.96), Hb 
(11.16 ± .299) and platelets (032.54 ± 21.68) levels in comparison to normal control subjects. An elevation of 
LDH and ferritin levels in cases of carcinoma breast signifies its importance as a biomarker of disease. A serial 
measurement of these enzymes would have diagnostic and prognostic significance and help treatment 
decisions.  
Conclusion: The ferritin along with lactate dehydrogenase can be used as a valuable biomarker for breast cancer 
diagnosis and prognosis. 
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Introduction  
Breast cancer is perhaps the most frequently diagnosed 
cancer in females plus a major cause of cancer 
moralities worldwide [12]. The breast cancer is the most 
frequently occurring in developed and developing 
countries with an estimation of 690,000 new cases in 
each region [2]. In 2008 there was an estimation of 23% 
(1.38 million) of total new cancer cases and 14% 
(458,400) of the total cancer deaths. The incidence rate 
of breast cancer has been sharply decreased in some of 
these countries including the United States, United 
Kingdom, France and Australia and has also been 
decreasing in North America and many European 
countries. The breast cancer incidence and mortality 
rates have been increasing in many African and Asian 
countries including Uganda, South Korea, and India [12].  
The incidence rate of breast cancer is highest in 
Pakistan than any other Asian country. In Western 
population breast cancer is common at older age but in 
Pakistan it is more common at young age and maximum 
patients are represented with later stages of cancer 
(Stage 3 and 4) [3]. A 50 year age-cut point is found 
effective in assessing prognostic factor in breast cancer 
[10]. In Pakistan, there is estimation of 90000 new cases 
and 40000 breast cancer related deaths annually. It is 
estimated that one out of nine Pakistani women is likely 
to suffer from breast cancer [13]. 
Tumor markers are substances produced by the 
cancer cells or other cells of body in response to cancer 
or other noncancerous conditions. These are found in 
blood, stool, other body fluids, or tissues of some 
patients with cancer. Tumor markers may be used in 
diagnosis, prediction of patient’s response to treatment 
or determine whether cancer has returned [7]. The stage 
IV patients were determined through lymph node 
evaluation that can provide important prognostic 
information [16]. There is high need to investigate further 
tumor markers for diagnosis and treatment management 
of cancer. Moreover, such simple, affordable and 
practicable biochemical tests are needed because the 
analytical methods of many existing tumor marker tests 
are unapproachable for general population as the 
facilities for these are available at only sophisticated and 
well equipped centers with latest technology. The 
present study is undertaking to assess the clinical utility 
of certain biochemical investigations that include LDH, 
GGT, Ferritin, HB, platelets, ALP, AST, ALT, and 
bilirubin, to find out useful biomarker (s) that may help in 
breast cancer diagnosis and prognosis.     
Methods 
Fifty breast cancer victims that were admitted to the 
institute of nuclear medicine and oncology, Lahore were 
included in this study. To direct the research an 
endorsement of host Institutional Bioethics Committee 
was taken. Out of 50 patients, 24% of patients were 
diagnosed with invasive ductal carcinoma. Only 1% of 
patients had medullary and invasive lobular carcinoma. 
The age of the patients was in the range of 28-64 years. 
The patients were clinically categorized as stage 2 (19) 
and stage 3 (29), respectively. A questionnaire was 
designed to obtain the information of breast cancer 
patients including patient’s name, age, marital status, 
duration of disease, duration of treatment, family history 
of breast cancer, history of mastectomy, and past 
medical history. Clinical data of patients was obtained 
from patient’s files. An informed consent was held and 
20 control subjects were also enrolled. The age group of 
control subjects was within the range of 25-45. Entire 
research work was conducted in biochemical lab of the 
institute of nuclear medicine and oncology. Blood 
samples (5ml) were collected with the help of expert 
technicians and consent of patients. Serum from blood 
samples were separated by centrifugation at 3000rpm 
for 10 minutes and stored at -20oC prior to processing. 
Twelve biochemical parameters were analyzed in this 
study by using enzyme kits. These parameters included,  
hemoglobin (Hb), platelets, white blood cells (WBCs), 
alkaline phosphatase (ALP), alanine transferase (ALT), 
aspartate aminotranferase (AST), bilirubin, blood urea 
nitrogen (BUN), creatinine, lactate dehydrogenase 
(LDH), ferritin and gamma glutamyl transferase (GGT). 
The obtained data was analyzed by using software 
statistical package for The Social Science (SPSS 
Version 13). Frequency and descriptive analyses were 
used to describe the data. Student T test was also used 
to differentiate between two numerical data. 
Results 
Patient’s characteristics: 50 breast cancer patients 
(Stage 1, 2, 3) and 10 control subjects were studied. The 
age of patients was ranged between 28 and 64. 13.5 % 
of patients were suffering from disease for more then 1-
2 years and 11.5 % for less than 3-9 months. Out of 50 
patients, 11 patients had family history and 39 patients 
had no family history. Majority of patients were 
histologically identified with invasive ductal carcinoma 
(IDC). 14.5% of patients had been mestectomized. The 
general patient characteristics are shown in Table 1. 
General characters No. of cases Percentage (%) 
Age (years)             
28-40 19 9.5 
41-50 17 8.5 
51-64 14 7 
Disease duration 
>1-2 (years) 27 13.5 
<3-9 (month) 23 11.5 
Family history 
                  Positive 11 5.5 
                  Negative 39 19.5 
Histologic type 
IDC 48 24 
ILC 1 .00095 
Medullary 1 .00095 
Stage of tumor 
Stage 1  0   0 
Stage 2 31 15.5 
  Stage 3 19 9.5 
Cancer site 
Left   18 9 
right 32 16 
Surgery 
                   Yes 29 14.5 
                    No 21 10.5 
Receptor Status 
                   Positive 17 8.5 
Negative 33 16.5 
Table 1: Demographic and general health indicators of Patients  
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Serum ferritin in breast cancer: The results are 
summarized in table 2. After statistical analysis it has 
been cleared that the control subjects had the mean 
serum ferritin concentration of 263.60 ng/l. The women 
with breast cancer had mean ferritin concentration of 
356.46 ng/l with standard deviation of 86.87. The 
difference between the means of two groups (control, 
patients) is significant (P<0.005). However there was no 
difference in serum ferritin in different stages of cancer. 
Serum LDH in breast cancer: Serum LDH levels were 
also raised in cancer patients then the control group. The 
mean LDH value was 221.48 with standard deviation of 
130.37 in cancer group. And the mean serum LDH 
concentration in control subjects was 346.20. So the 
LDH concentration was significantly higher in breast 
cancer patients (P<0.005) then the healthy controls. 
Serum GGT in breast cancer: The statistical analysis 
of data showed that there was no significant difference 
(P>0.005) in GGT concentration in both the control and 
patients groups. The results of both groups were in 
normal range.  
Liver functioning tests (LFT’S) in breast cancer: 
There was no significant difference (P>0.005) in the 
concentrations of ALP, AST, ALP, bilirubin between 
breast cancer patients (stage0-III) and healthy controls. 
Hematological parameters in breast cancer: The 
hematological parameter hemoglobin was in normal 
range in breast cancer patients. Platelets were in raised 
concentration in many patients but statistically there was 
no significant difference (P>0.005) in Hb and platelets 
concentrations between healthy controls and breast 
cancer patients. 
 
 
   Parameters  
                        Mean ± S.E 
                             (range)   
 
 
     P-value         Patient group     Control group 
Ferritin             356.46 ± 12.28) 
         (37-432) 
       263.60 ± 23.40 
          (166-403) 
    <0.005 
LDH                            221.48 ± 18.44 
         (210-477) 
       346.20 ± 17.41 
           (275-423) 
    <0.005 
GGT 
 
     34.12 ± 1.61 
          (17-56) 
       30.70 ± 2.47 
            (19-42) 
    >0.005 
ALP 
 
     279.27 ± 26.60 
         (146-1127) 
       227.7 ± 15.05 
            (176-336) 
    >0.005 
AST 
 
     49.44 ± 8.510 
         (15-345) 
        21.7 5 ±.1.87 
             (13-34) 
    >0.005 
ALT 
 
     33.40 ± 2.83 
         (10-114) 
        29.0 ± 2.36 
             (16-40) 
    >0.005 
Bilirubin 
  
     4.87 ± 3.96 
         (0.5-1.3) 
         4.54 ± .26 
            (3.5-5.8)   
    >0.005 
BUN        10.79 ± .81 
         (0.6-31.7) 
         12.7 ± 1.08 
            (7-18) 
    >0.005 
Creatinine        1.03 ± .22 
         (0.7-1.3) 
          0.9 ± .05 
           (0.7-1.1) 
    >0.005 
Hemoglobin      11.16 ± .40 
         (9.5-11.9) 
         11.59 ± .35 
             (10-13.7) 
   >0.005 
Platelets      302.54 ± 21.68  
         (57-70)                             
         280.9 ± 25.63 
             (207-396) 
   >0.005 
Table 2: Comparison of biochemical parameters in both patients 
and control groups highlighting significant P-values (<0.005) for 
Ferritin and LDH. 
Group     LDH/Ferritin (Mean ± S.D) 
Patient      2.67  ±  2.67 
Control      1.310  ±  0.39 
Table 3: Mean value ratio (LDH/Ferritin) in non-metastatic 
breast cancer patients and control group 
 
Figure 1: A representation of statistically significant biochemical 
parameters (ferritin and LDH) showing higher ferritin and lactate 
dehydrogenase concentration in cancer patients in comparison to 
healthy females (i.e. P<0.005). 
 
Figure 2: Comparison between control and breast cancer groups 
for measured biochemical parameters AST, ALT, ALP, and 
platelets (PLT). 
Discussion 
In the present study, mean levels of lactate 
dehydrogenase was 346.20 ± 55.06 U/L, 221.48 ± 
130.37 U/L in controls and breast cancer patients 
respectively. The mean values of lactate dehydrogenase 
were found significantly raised, when compared to 
controls. There was significant rise (P<0.005) in LDH 
levels in breast cancer as compared to healthy subjects 
(fig. 1). The results of our study are in congruent with 
Mishra who estimated the serum LDH in 102 breast 
cancer patients and find it to be elevated [14]. 
Fentimen and Allen also reported a similar increase of 
serum LDH. They had done a study on 96 breast cancer 
patients [8]. Our findings were similar to the study by 
Chandrakanth who reported a significant increase in 
LDH in his study of 60 breast cancer patients [5]. Seth 
and his colleagues, in a study involving 25 breast cancer 
patients also determined significantly higher values of 
serum LDH [15]. 
In our study the mean values of serum ferritin was 
263.60 ± 74.00 and 356.46 ± 86.87 in healthy females 
and carcinoma breast respectively. The serum ferritin 
was significantly elevated in breast cancer as compared 
to healthy subjects (fig. 1). Our findings of serum ferritin 
are in agreement with the results of study carried out by 
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Jacobs and his colleagues who witnessed a significant 
increase in serum ferritin concentration in carcinoma 
breast patients [11]. Cujic evaluated the 57 breast cancer 
patients for serum ferritin and he also found that ferritin 
concentration was raised in breast carcinoma patients 
[6]. Bilirubin and ALP are not significantly raised 
(P>0.005) in our study. Our study results are similar to 
Anuradha’s study. She also found that ALP and bilirubin 
levels were not raised in breast carcinoma, when 
compared to controls [1]. Mishra also assessed that the 
level of heamoglobin and ALP in breast carcinoma 
patients was not significantly higher and coincides with 
our analysis where we also found that there was no 
substantial increase in serum Hb and ALP in breast 
cancer patients as compared to controls [14]. There is 
also a link with another study in which 249 breast cancer 
patients were tested for serum Hb, and no substantial 
increase was found compared to controls [3].  
Our findings were similar to Veni, who reported that 
there was no significant rise in bilirubin concentration as 
compared to controls [17]. The results of Cao and Wang 
study also correlates with our study. He found that ALT, 
AST and ALP concentrations were not significantly 
raised in breast cancer patients without distant 
metastasis as compared to breast cancer patients with 
liver metastasis [4]. 
It was concluded from this study that ferritin along with 
lactate dehydrogenase can be used as a useful 
biomarker for the diagnosis and prognosis of breast 
cancer.  
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